Navigation Links
Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
Date:4/10/2013

WASHINGTON, April 10, 2013 /PRNewswire/ -- Novocure announced today that new data from preclinical testing of NovoTTF Therapy in non-small cell lung carcinoma (NSCLC), ovarian and pancreatic cancer has been presented at the 2013 AACR Annual Meeting.  The new data builds on existing published research describing the potential efficacy of NovoTTF Therapy in a wide range of solid tumors.

"The results presented at the AACR Annual Meeting demonstrate that NovoTTF Therapy inhibits the growth of squamous histology non-small cell lung cancer as well as pancreatic and ovarian cancers in preclinical models," said Eilon Kirson , M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development.  "We intend to build on this research through clinical trials evaluating the efficacy of NovoTTF Therapy in these indications when delivered in combination with chemotherapy."

AACR Annual Meeting 2013 Abstracts

  • Giladi et al, Development of an orthotopic squamous cell carcinoma (SCC) lung cancer model.  Data were presented describing a new in vivo model to test the efficacy of anti-neoplastic treatments in SCC lung cancer.  Abstract #340.
  • Giladi et al, NovoTTF Therapy inhibited the growth of pancreatic and ovarian cancer in vitro. Additionally, the data supports a conclusion that modulation of NovoTTF Therapy frequency may overcome treatment resistance. Abstract #5569.

About NovoTTF Therapy
NovoTTF Therapy is delivered by portable, non-invasive medical devices designed for continuous use throughout the day by the patient. NovoTTF Therapy has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The delivery systems weigh about six pounds and create a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. The NovoTTF-100A System is not approved in the US for any indications except for recurrent glioblastoma brain tumors. The safety and effectiveness of NovoTTF Therapy in lung, pancreas and ovarian cancers has not been established.

About Novocure™
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure's US operations are based in New York, NY and Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Contact:
Frank Leonard
(212) 767-7536
media@novocure.com  


'/>"/>
SOURCE Novocure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
2. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
3. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
4. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
5. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
6. Cardium Presents Year-End 2012 Financial Results And Recent Developments
7. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
8. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
9. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
10. Versus Presents New Hand-Hygiene Alliance, Wireless Sensors and RTLS Education at HIMSS13
11. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
Breaking Medicine News(10 mins):